Novasep und Pharmazell/Farmabios fusionieren zu Axplora
Nach dem Zusammenschluss der Pharma-Entwicklungs- und Synthesedienstleister (Contract Development & Manufacturing Organizations, CDMOs) Novasep und Pharmazell im April dieses Jahres steht nun der Name des neuen Unternehmens fest.
The new brand illustrates the innovative mindset driving the company and its employees and the desire to be a partner of choice for complex active pharmaceutical ingredients, its creators said. The tagline “Reliable partner. Agile explorer” encapsulates the explorer spirit that the company fosters within its own organization and with its partners.
As a manufacturing partner for pharmaceutical and biotechnology companies worldwide, CEO Sylke Hassel, who was formerly CEO of PharmaZell, said the units making up Axplora have a long track record of reliably developing and scaling up complex production processes and delivering medicines on time and at scale.
Going forward, Hassel said, the merged company headquartered at Raubling near Munich, with nine industrial sites in Europe and India and an R&D facility in the US, will leverage its technology and knowledge to deliver the full customer-centered lifecycle from innovation to generic.
Axplora will offer added security of supply for clients at the highest standards and its global footprint will enable it to optimize supply chain logistics.
On completion of the merger last spring, the combined PharmaZell and Novasep had sales of nearly €500 million. Axplora employs 2,400 people worldwide.
Along with small molecule and biomolecular active pharmaceutical ingredients, the newly named company’s portfolio includes products that address lifestyle-induced respiratory, inflammatory and liver diseases.
Author: Dede Williams, Freelance Journalist
